Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

July 31, 2004

Study Completion Date

July 31, 2004

Conditions
Osteoarthritis
Interventions
DRUG

Buprenorphine transdermal patch

Buprenorphine transdermal patch applied for 7-day wear.

Trial Locations (36)

28210

The Arthritis Clinic and Carolina Bone and Joint, Charlotte

29118

The Arthritis and Osteoporosis Center, Orangeburg

33140

Miami Beach Anesthesiology Associates, Miami Beach

33186

Lifespan Research Foundation, Inc., Miami

33321

West Broward Rheumatology Association, Inc., Tamarac

34102

Neuro Science and Spine Assoc., Naples

35007

Southern Drug Research, Birmingham

40509

Bluegrass Orthopaedics, Lexington

42431

Commonwealth Biomedical Research, LLC, Madisonville

45402

Dayton Primary and Urgent Care, Dayton

48917

PCM Medical Services, Lansing

49009

Westside Family Medical Center, Kalamazoo

53566

Monroe Medical Foundation, Monroe

63141

HealthCare Research LLC, St Louis

66160

University of Kansas Medical Center, Kansas City

70128

Dolby Providers, Inc., New Orleans

71603

Private Practice, Pine Bluff

71913

Hot Springs Mercy Pain Clinic, Hot Springs

75080

KRK Medical Research, Richardson

75235

Renaissance Clinical Research & Hypertension Clinic, Dallas

77074

Spine Care Southwest., Houston

78759

CEDRA Clinical Research,, Austin

83702

Intermountain Orthopaedics, Boise

85029

Redpoint Research, Phoenix

85712

Advanced Clinical Therapeutics, Tucson

Tucson Orthopedic Institute, Tucson

90211

Lovelace Scientific Resources, Beverly Hills

90404

Univ. of Southern California, Santa Monica

90620

Southbay Pharma Research, Buena Park

92025

Kaiser Permanente, Escondido

92801

Advanced Clinical Research Institute, Anaheim

93611

Community Medical Providers, Clovis

97504

The Medford Medical Clinic, Medford

06708

Arthritis Center of CT, Waterbury

01610

Clinical Pharmacology Study Group, Worcester

03825

Northeast Pain Research Center, Barrington

All Listed Sponsors
lead

Purdue Pharma LP

INDUSTRY

NCT00312572 - Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain | Biotech Hunter | Biotech Hunter